Swedish Orphan Biovitrum AB SOBI

WALTHAM, Mass., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB (Sobi®), today announced that the US Food and Drug Administration (FDA) has granted Fast Track designation to pacritinib for the treatment of VEXAS syndrome. Pacritinib is a dual IRAK1/JAK2 inhibitor currently in Phase ll development for VEXAS syndrome. Fast Track designation is designed to facilitate the development and expedite the review of medicines to treat seri

The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 6 May 2026 resolved on a directed issue of redeemable and convertible class C shares and to authorise the Board of Directors to resolve on the repurchase of all issued class C shares through an acquisition offer directed to all owners of class C shares in Sobi. The Board of Directors of Sobi has, as previously communicated, on 15 July 2026 resolved to, conditional upon subscription and payment from Svenska Handelsbanken